119140 Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem

119140
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité
      Click To Print This Page

      Aperçu

      Replacement Information

      Prix & Disponibilité

      RéférenceDisponibilité Conditionnement Qté Prix Quantité
      119140-10MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 10 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
          Catalogue Number119140
          Brand Family Calbiochem®
          Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
          References
          ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
          de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
          Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
          Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
          Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
          Cusack, N., et al. 1981. Br J Pharm.72, 443.
          Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
          Product Information
          CAS number35920-39-9
          FormWhite solid
          Hill FormulaC₁₂H₁₆N₆O₄
          Chemical formulaC₁₂H₁₆N₆O₄
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary Target K<sub>i</sub>14 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Certificats d'analyse

          TitreNuméro de lot
          119140

          Références bibliographiques

          Aperçu de la référence bibliographique
          Forster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
          de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
          Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
          Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
          Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
          Cusack, N., et al. 1981. Br J Pharm.72, 443.
          Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision28-March-2013 JSW
          Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
          DescriptionA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number35920-39-9
          Chemical formulaC₁₂H₁₆N₆O₄
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityDMSO (50 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
          de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
          Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
          Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
          Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
          Cusack, N., et al. 1981. Br J Pharm.72, 443.
          Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.